bosutinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4359 380843-75-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • WAY-173606
  • bosutinib
  • bosulif
  • bosutinib monohydrate
  • bosutinib hydrate
  • SKI-606
  • SKI 606
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases
  • Molecular weight: 530.45
  • Formula: C26H29Cl2N5O3
  • CLOGP: 4.94
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 1
  • TPSA: 82.88
  • ALOGS: -4.75
  • ROTB: 9

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 4, 2012 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1367.17 35.90 396 762 83168 2273759
Nausea 545.48 35.90 219 939 111970 2244957
Rash 266.13 35.90 111 1047 59447 2297480
Vomiting 262.68 35.90 116 1042 71486 2285441
Fatigue 225.32 35.90 110 1048 84763 2272164
Pleural effusion 134.48 35.90 44 1114 11624 2345303
Abdominal pain 116.11 35.90 53 1105 34321 2322606
Neoplasm progression 111.89 35.90 31 1127 4637 2352290
Chronic myeloid leukaemia 104.67 35.90 20 1138 566 2356361
Abdominal pain upper 100.27 35.90 42 1116 22058 2334869
Dyspnoea 75.06 35.90 53 1105 78680 2278247
Headache 69.59 35.90 51 1107 80128 2276799
Pyrexia 67.53 35.90 43 1115 53665 2303262
Constipation 65.47 35.90 31 1127 21598 2335329
Cytogenetic analysis abnormal 62.26 35.90 10 1148 98 2356829
Malaise 61.29 35.90 41 1117 55544 2301383
Hepatic enzyme increased 59.43 35.90 23 1135 9779 2347148
Decreased appetite 54.20 35.90 30 1128 28861 2328066
Death 53.53 35.90 44 1114 81424 2275503
Pneumonia 48.66 35.90 34 1124 49262 2307665
Pulmonary oedema 47.19 35.90 18 1140 7345 2349582
Bone pain 47.12 35.90 19 1139 8977 2347950
Drug intolerance 45.59 35.90 21 1137 13696 2343231
Pericardial effusion 41.56 35.90 14 1144 3995 2352932
Arthralgia 41.27 35.90 32 1126 54253 2302674
Asthenia 40.85 35.90 30 1128 46896 2310031
Cytopenia 39.97 35.90 10 1148 999 2355928
Disease progression 38.30 35.90 20 1138 17075 2339852
Capillary leak syndrome 37.99 35.90 8 1150 371 2356556
Pain 37.60 35.90 32 1126 61825 2295102

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 930.95 38.76 298 794 53554 1692135
Nausea 266.91 38.76 121 971 51075 1694614
Pleural effusion 203.13 38.76 66 1026 11044 1734645
Fatigue 190.23 38.76 96 996 50685 1695004
Neoplasm progression 146.43 38.76 39 1053 3228 1742461
Chronic myeloid leukaemia 138.76 38.76 28 1064 670 1745019
Rash 129.23 38.76 68 1024 38625 1707064
Vomiting 115.65 38.76 63 1029 38252 1707437
Abdominal pain 114.29 38.76 52 1040 21438 1724251
Cytogenetic analysis abnormal 105.07 38.76 16 1076 63 1745626
Abdominal discomfort 88.79 38.76 34 1058 9047 1736642
Drug intolerance 86.46 38.76 30 1062 6032 1739657
Dyspnoea 66.82 38.76 50 1042 52009 1693680
Disease progression 64.85 38.76 33 1059 17230 1728459
Acquired gene mutation 64.50 38.76 12 1080 183 1745506
Fluid retention 62.66 38.76 21 1071 3788 1741901
Headache 60.24 38.76 40 1052 34336 1711353
Arthralgia 58.02 38.76 34 1058 23410 1722279
Drug resistance 57.89 38.76 19 1073 3211 1742478
Cardiac failure 55.91 38.76 27 1065 12575 1733114
Death 49.75 38.76 53 1039 87390 1658299
Pruritus 45.42 38.76 29 1063 23193 1722496
Peripheral swelling 44.38 38.76 20 1072 7951 1737738
Second primary malignancy 44.29 38.76 12 1080 1047 1744642
Abdominal pain upper 41.14 38.76 21 1071 10980 1734709
Decreased appetite 39.83 38.76 27 1065 23844 1721845
Pain 39.44 38.76 28 1064 26629 1719060

Pharmacologic Action:

SourceCodeDescription
ATC L01XE14 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Blastic phase chronic myeloid leukemia indication 413656006
Chronic Myelocytic Leukemia Accelerated Phase indication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 6.69 Basic
pKa3 4.74 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Dec. 19, 2020 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL Dec. 19, 2020 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Dec. 19, 2020 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Dec. 19, 2024 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL Dec. 19, 2024 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Dec. 19, 2024 TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR Kd 9 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 10.54 CHEMBL CHEMBL
Tyrosine-protein kinase HCK Kinase INHIBITOR Kd 8.47 CHEMBL CHEMBL
Tyrosine-protein kinase Lyn Kinase INHIBITOR Kd 8.38 CHEMBL CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 8.70 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 5.29 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.80 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.66 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.96 CHEMBL
Myosin-IIIb Kinase Kd 5.64 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.59 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 5.24 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.80 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.43 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 8.04 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 5.96 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 5.82 CHEMBL
Cyclin-G-associated kinase Kinase Kd 8.89 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.46 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.09 CHEMBL
Casein kinase I isoform delta Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 5.77 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.10 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 5.49 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 6.54 CHEMBL
Serine/threonine-protein kinase PLK1 Kinase Kd 5.74 CHEMBL
Wee1-like protein kinase Kinase Kd 6.29 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 8.32 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 5.23 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.32 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.60 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.82 CHEMBL
Serine/threonine-protein kinase Nek11 Kinase Kd 6.19 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 8.20 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 5.34 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 5.43 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 7 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 5.77 CHEMBL
Dual specificity protein kinase CLK3 Kinase Kd 6.52 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 5.77 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 8.85 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 6.28 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 6.22 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 8.05 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 7.74 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 8.24 CHEMBL
Serine/threonine-protein kinase tousled-like 2 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 8.15 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 6.44 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 5.44 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.64 CHEMBL
Protein kinase C epsilon type Kinase Kd 5.62 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 8.40 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.49 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 7.49 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.77 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.60 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 5.89 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.51 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 6.70 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.06 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.62 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 5.92 CHEMBL
Myosin-IIIa Kinase Kd 5.21 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 5.68 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.89 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 6.05 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 6.96 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 9.30 CHEMBL
Misshapen-like kinase 1 Kinase Kd 8.49 CHEMBL
Casein kinase I isoform alpha-like Kinase Kd 5.59 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 6.30 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.24 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 6.44 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 7.14 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6.46 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.59 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.57 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 5.96 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.51 CHEMBL
Megakaryocyte-associated tyrosine-protein kinase Kinase Kd 5.24 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 6.11 CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Kinase Kd 6.46 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 8.33 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.49 CHEMBL
Macrophage-stimulating protein receptor Kinase Kd 5.20 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.35 CHEMBL
Serine/threonine-protein kinase PAK 1 Kinase Kd 5.64 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.22 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6.43 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.26 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 5.80 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 5.41 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 5.49 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 6.70 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 7.57 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.35 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 7.74 CHEMBL
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) Kinase IC50 6.82 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 6.47 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 7.48 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 7.54 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 8.29 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.24 CHEMBL
NT-3 growth factor receptor Kinase Kd 5.47 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.80 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 5.35 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.52 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.34 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.82 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 1 Kinase Kd 6.20 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 6.02 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.24 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 6.41 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 8.48 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.41 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 7.28 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 7 Kinase Kd 5.28 CHEMBL
Peripheral plasma membrane protein CASK Kinase Kd 6.08 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 6.42 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 9.11 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 5.52 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 7.54 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.47 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 7 CHEMBL
Casein kinase I isoform alpha Kinase Kd 6.55 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.36 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase 32A Kinase Kd 5.74 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 7.19 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 6.42 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 7.96 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 8.96 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 7.03 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 6.42 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 5.30 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 6.85 CHEMBL
Protein kinase C delta type Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.54 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 5.27 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.85 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 6.57 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 5.42 CHEMBL
Myotonin-protein kinase Kinase Kd 7.04 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.92 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 8.09 CHEMBL
Serine/threonine-protein kinase PAK 2 Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 7.21 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.48 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 9.23 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.57 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.52 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.80 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 7.28 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.92 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.66 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 8.08 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 8 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.59 CHEMBL
Serine/threonine-protein kinase tousled-like 1 Kinase Kd 6.24 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.41 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 7.14 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 6.15 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.89 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 6.16 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 6.68 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.17 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 5.49 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.48 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 7.27 CHEMBL
Bcr/Abl fusion protein Kinase IC50 7.70 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.66 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.18 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 6.92 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.34 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 5.66 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 5.52 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 5.54 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 7.52 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 8.51 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 6.96 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 7.72 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5.64 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6 CHEMBL
Epidermal growth factor receptor Kinase Kd 7.74 CHEMBL
Protein kinase C theta type Kinase Kd 6.04 CHEMBL
Tyrosine-protein kinase Blk Kinase IC50 8.14 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 5.26 CHEMBL

External reference:

IDSource
4031718 VUID
N0000185728 NUI
C1831731 UMLSCUI
D03252 KEGG_DRUG
5018V4AEZ0 UNII
8715 INN_ID
703586005 SNOMEDCT_US
1307619 RXNORM
28803 MMSL
d07901 MMSL
014636 NDDF
4031718 VANDF
703128001 SNOMEDCT_US
918639-08-4 SECONDARY_CAS_RN
CHEMBL288441 ChEMBL_ID
DB8 PDB_CHEM_ID
DB06616 DRUGBANK_ID
CHEBI:39112 CHEBI
5710 IUPHAR_LIGAND_ID
5328940 PUBCHEM_CID
C471992 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0135 TABLET, FILM COATED 100 mg ORAL NDA 19 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0136 TABLET, FILM COATED 500 mg ORAL NDA 19 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0193 TABLET, FILM COATED 400 mg ORAL NDA 19 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 63539-117 TABLET, FILM COATED 100 mg ORAL NDA 18 sections